STUDIO DI FASE III, MULTICENTRICO, RANDOMIZZATO, IN DOPPIO CIECO, CONTROLLATO CON PLACEBO, A GRUPPI PARALLELI PER VALUTARE L EFFICACIA E LA SICUREZZA DI LENALIDOMIDE (REVLIMID) VERSO PLACEBO IN SOGGETTI AFFETTI DA ANEMIA TRASFUSIONE-DIPENDENTE DOVUTA A SINDROMI MIELODISPLASTICHE A RISCHIO BASSO O INTERMEDIO-1 SECONDO I CRITERI IPSS, SENZA ANOMALIA CITOGENETICA DA DELEZIONE 5Q[31] E NON RESPONSIVI O REFRATTARI AI FATTORI DI CRESCITA ERITROPOIETICI - ND

Celgene Corporation0 个研究点目标入组 375 人开始时间: 2010年1月28日最近更新: 2018年9月17日

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: Celgene Corporation
入组人数: 375

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1.Must understand and voluntarily sign an informed consent form. 2.Age ≥ 18 years at the time of signing the informed consent form. 3.Must be able to adhere to the study visit schedule and other protocol requirements including willingness to undergo bone marrow aspirate and biopsy as indicated in the study protocol. 4.Must be able to complete patient-reported outcome assessments either independently or with minimal assistance from trained clinic personnel or caregiver. 5.Must have a documented diagnosis of MDS according to WHO 2008 classification (Brunning, 2008) associated with the following features: - IPSS low or intermediate-1 risk - Any karyotype except del 5q [31] (at least 20 analyzable metaphases are required for standard G-banding cytogenetic analysis at screening). 6.Must have transfusion-dependent anemia that meets the following criteria: - Average transfusion requirement of ≥2 units /28 days of pRBCs confirmed for a minimum of 112 days immediately preceding randomization. - No consecutive 56 days that was RBC transfusion-free during the 112 days immediately preceding randomization. 7.Must be unresponsive or refractory to erythropoiesis-stimulating agents, based on one of the following two criteria: - Transfusion-dependence in subjects previously treated with an ESA (requires a minimum ESA trial of > 40,000 U/week r-HuEPO x 8 weeks or equivalent dose of darbepoetin), or - Serum erythropoietin level of > 500 mU/mL (measured when Hgb < 9.5 g/dL) in subjects not previously treated with an ESA. 8.Must have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2. 9.Concurrent corticosteroids used for medical conditions other than MDS is allowed provided subject is on a stable or decreasing dose for ≥ 1 week prior to randomization. 10.Females of childbearing potential (FCBP) must undergo pregnancy testing based on the frequency outlined in Appendices 21.2 and 21.3 and 21.4 and pregnancy results must be negative. 11.Unless practicing complete abstinence from heterosexual intercourse, sexually active FCPB must agree to use adequate contraceptive methods as specified in Appendices 21.2 and 21.3 and 21.4. 12.Males (including those who have had a vasectomy) must use barrier contraception (condoms) when engaging in sexual activity with FCBP as specified Appendices 21.2 and 21.3 and 21.4. 13.Males must agree not to donate semen or sperm during the duration specified in Appendices 21.2 and 21.3 and 21.4. 14. All subjects must: - Understand that the investigational product could have a potential teratogenic risk. - Agree to abstain from donating blood while taking investigational product and following discontinuation of investigational product (see Appendices 21.2 and 21.3 and 21.4) - Agree not to share investigational product with another person. - Be counseled about pregnancy precautions and risks of fetal exposure (see Appendices 21.2 and 21.3 and 21.4).
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

排除标准

•1.Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form. 2.Pregnant or lactating females. 3.Prior history of malignancies, other than MDS, unless the subject has been free of the disease for ≥ 3 years. However, subjects with the following history/concurrent conditions may enroll at any time: - Basal cell carcinoma of the skin - Carcinoma in situ of the cervix - Incidental histologic finding of prostate cancer (Tumor Node Metastasis (TNM) stage of T1a or T1b) 4. Known Human Immunodeficiency Virus (HIV), active Hepatitis B Virus (HBV) and/or Hepatitis C Virus (HCV) infection. 5.Prior therapy with lenalidomide. 6.Any of the following laboratory abnormalities: - Absolute neutrophil count (ANC) < 500/μL (0.5 x 109/L) - Platelet count < 50,000/μL (50 x 109/L) - Serum aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) or alanine transaminase (ALT)/serum glutamate pyruvate transaminase (SGPT) > 3.0 x upper limit of normal (ULN) - serum bilirubin levels > 1.5 x ULN; serum bilirubin levels > 1.5 x ULN are acceptable if these can be attributed to ineffective erythropoiesis (as indicated by bone marrow findings). Subjects with ineffective erythropoiesis may have a decreased haptoglobin level, elevated indirect bilirubin level and/or lactate dehydrogenase level. Autoimmune hemolytic anemia (as indicated by positive Coombs testing) is an exclusion criterion. 7. Hypersensitivity to thalidomide including - Prior ≥ grade-2 National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v 3.0 allergic reaction to thalidomide - Prior desquamating (blistering) rash while taking thalidomide 8.Renal insufficiency (CrCl < 60 mL/min by Cockroft-Gault method) 9.Uncontrolled hyperthyroidism or hypothyroidism. 10.≥ Grade-2 neuropathy. 11.Use of cytotoxic chemotherapeutic or investigational agents to treat MDS within 28 days prior to randomization or ongoing adverse events from previous treatment with investigational drugs, regardless of the time period. 12.Use of an erythropoiesis stimulating agent within the 56 days prior to randomization. 13.Prior allogeneic or autologous stem cell transplantation. 14.Concurrent use of androgens other than to treat hypogonadism. 15.Clinically significant anemia due to iron, B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or gastrointestinal bleeding. - If marrow stain for iron is not available, the transferrin saturation (iron/total iron binding capacity Fe/TIBC) must be >20% or serum ferritin must be >100 ng/dL. 16.Prior history of deep venous thrombosis (DVT) or pulmonary embolus (PE) within 3 years of randomization. 17.Significant active cardiac disease within the previous 6 months including: - New York Heart Association class II-IV congestive heart failure - Unstable angina or angina requiring surgical or medical intervention - Myocardial infarction

研究者

发起方

Celgene Corporation

相似试验

进行中（未招募）

1 期

ESTUDIO DE FASE III, MULTICÉNTRICO, ALEATORIZADO, ABIERTO DE AZACITIDINA (VIDAZA®) FRENTE A LAS PAUTAS CONVENCIONALES PARA EL TRATAMIENTO DE ANCIANOS CON LEUCEMIA MIELOIDE AGUDA DE NUEVO DIAGNÓSTICO. A phase 3, multicenter, randomized, open-label, study of azacitidine (Vidaza®) versus conventional care regimens for the treatment of older subjects with newly diagnosed acute myeloid leukemia.

EUCTR2009-012346-23-ESCelgene Corporation480

进行中（未招募）

1 期

ESTUDIO DE FASE III, MULTICÉNTRICO, ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO, EN GRUPOS PARALELOS PARACOMPARAR LA EFICACIA Y LA SEGURIDAD DE LENALIDOMIDA (REVLIMID®) FRENTE A PLACEBO EN SUJETOS CON ANEMIA DEPENDIENTE DETRANSFUSIONES DEBIDO A SÍNDROMES MIELODISPLÁSICOS CON RIESGO BAJO OINTERMEDIO-1 DEL IPSS SIN DELECCIÓN 5Q[31] Y NO RESPONDEDORES O REFRACTARIOS A FÁRMACOS ESTIMULANTES DE LA ERITROPOYESIS.(A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to compare the efficacy and safety of lenalidomide (Revlimid) versus placebo in subjects with transfusion-dependent anemia due to IPSS low or intermediate-1 risk myelodysplastic syndromes without deletion 5q[31] and unresponsive or refractory to erythropoiesis-stimulating agents).ANEMIA DEPENDIENTE DE TRANSFUSIONES DEBIDO A SÍNDROMES MIELODISPLÁSICOS CON RIESGO BAJO O INTERMEDIO-1 DEL IPSS SIN DELECCIÓN 5Q[31] Y NO RESPONDEDORES O REFRACTARIOS A FÁRMACOS ESTIMULANTES DE LA ERITROPOYESIS.(Transfusion-dependent anemia due to International Prognostic Scoring System (IPSS) low or intermediate-1 risk myelodysplastic syndromes (MDS) associated with any karyotype except deletion 5q[31] and unresponsive or refractory to erythropoiesis-stimulating agents (ESA).MedDRA version: 12.0Level: LLTClassification code 10068361Term: <Manually entered code. Term in E.1.1>

EUCTR2009-011513-24-ESCelgene Corporation375

进行中（未招募）

不适用

ESTUDIO DE FASE 3, MULTICÉNTRICO, ALEATORIZADO, EN DOBLE CIEGO YCONTROLADO CON PLACEBO DE ATX-101 (INYECCIÓN DE DESOXICOLATO DESODIO) FRENTE PLACEBO EN LA REDUCCIÓN DEL TEJIDO ADIPOSO SUBCUTÁNEOLOCALIZADO EN LA REGIÓN SUBMENTONIANA// Phase 3, multicenter, randomized,double-blind, placebo-controlled study of ATX-101 (sodium deoxycholate injection) versusplacebo for the reduction of localized subcutaneous fat in the submental area

EUCTR2010-020691-28-ESKythera Biopharmaceuticals, Inc.360

进行中（未招募）

不适用

EUCTR2010-020690-17-ESKythera Biopharmaceuticals, Inc.360

进行中（未招募）

不适用

ESTUDIO DE FASE 3, MULTICÉNTRICO Y ALEATORIZADO, COMPARATIVO DE LA SEGURIDAD Y LA EFICACIA DE LA ADMINISTRACIÓN SEMANAL DE TOCOSOL® PACLITAXEL FRENTE A LA ADMINISTRACIÓN SEMANAL DE PACLITAXEL INYECTABLE EN EL TRATAMIENTO DEL CÁNCER DE MAMA METASTÁSICOCANCER DE MAMA METASTÁSICO (CMM)

EUCTR2005-002428-33-ESSONUS Pharmaceuticals, Inc800